Pharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz

被引：15

作者：

Dailly, E

Allavena, C

Raffi, F

Jolliet, P

机构：

[1] Hop Hotel Dieu, Lab Pharmacol Clin, Dept Clin Pharmacol, F-44093 Nantes, France

[2] Hop Hotel Dieu, Dept Infect Dis, F-44093 Nantes, France

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2005年 / 60卷 / 01期

关键词：

efavirenz; interaction; lopinavir; pharmacokinetics;

D O I：

10.1111/j.1365-2125.2005.02369.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Aims The influence of efavirenz on lopinavir pharmacokinetics was investigated using a population approach. Methods Forty-five HIV patients treated with lopinavir/ritonavir plus efavirenz (A) and 24 patients treated with lopinavir/ritonavir plus nucleoside/nucleotide reverse transcriptase inhibitors (B) were studied. Results A relationship (P < 0.01) was established between the elimination rate constant of lopinavir (k(10)) and treatment with efavirenz. Mean k(10) was higher in group A than in group B (0.3838 vs 0.2810 h(-1)) (P < 0.001, 95% confidence interval for difference between means 0.1004, 0.1052). Conclusions These results suggest that lopinavir metabolism is induced by efavirenz.

引用

页码：32 / 34

页数：3

共 6 条

[1] The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers [J].

Aarnoutse, RE ;

Grintjes, KJT ;

Telgt, DSC ;

Stek, M ;

Hugen, PWH ;

Reiss, P ;

Koopmans, PP ;

Hekster, YA ;

Burger, DM .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (01) :57-67

[2]

DAILLY E, 2004, IN PRESS J CHROMAT B

[3]

DARIOSECQ JM, 2003, INFECT VIH MEMENTO T, P134

[4]

FERRE V, 2003, ANTIVIR THER S, V8, pS193

[5] Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients [J].

Hsu, A ;

Isaacson, J ;

Brun, S ;

Bernstein, B ;

Lam, W ;

Bertz, R ;

Foit, C ;

Rynkiewicz, K ;

Richards, B ;

King, M ;

Rode, R ;

Kempf, DJ ;

Granneman, GR ;

Sun, E .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (01) :350-359

[6] Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor [J].

Solas, C ;

Poizot-Martin, I ;

Drogoul, MP ;

Ravaux, I ;

Dhiver, C ;

Lafeuillade, A ;

Allegre, T ;

Mokhtari, M ;

Moreau, J ;

Lepeu, G ;

Petit, N ;

Durand, A ;

Lacarelle, B .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (04) :436-440

← 1 →